222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR18000202412019-01-012018-12-20Investigation for Risk Factors of Membrane Nephropathy in Guangxi and Study for Intervention of Vitamin DDisease diagnosis and treatment technology and standardized research and development and application demonstration Idiopathic membranous nephropathyVitamin D group:Active Vitamin D 0.5ug/day;Valsartan group:Valsartan capsule 160mg/day;Combined treatment group:Active vitamin D 0.5ug / day + valsartan capsule 160mg / day;The People's Hospital of Guangxi Zhuang Autonomous RegionNULLRecruiting14100BothVitamin D group:40;Valsartan group:40;Combined treatment group:40;China
2NCT01129557September 200921/5/2010Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseAldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney DiseaseProteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, MembranousDrug: Aliskiren;Drug: ValsartanColumbia UniversityNovartis PharmaceuticalsTerminated18 YearsN/AAll46Phase 4United States
3NCT00518219July 200716/8/2007To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)To Compare the Efficacy and Safety of TW vs Valsartan in the MNMembranous NephropathyDrug: TWNanjing University School of MedicineNULLCompleted18 Years65 YearsBoth68Phase 4China